Pediatric Clinical Trials Market, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Cardiovascular Diseases, and Neuropsychiatric Conditions, On

Pediatric Clinical Trials Market, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Cardiovascular Diseases, and Neuropsychiatric Conditions, Oncology, Diabetes, and Others (Neuropsychiatric Conditions, etc.)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

The pediatric clinical trials market is witnessing significant growth in recent times. Growing prevalence of chronic diseases among children and rising demand for new treatment options have boosted the pediatric clinical trials industry. Further, the market has witnessed rising investment from pharmaceutical companies for drug development targeting pediatric population. Growing awareness about rare diseases and various initiatives undertaken by regulatory bodies mandating clinical evaluation of drugs for pediatric use have augmented market opportunities. However, conducting clinical trials for pediatric drugs is more complex and challenging than adult trials due to ethical concerns, age specific drug metabolism, difficulty in recruitment, and lack of consensus over surrogate endpoints. Nevertheless, with emerging novel medical therapies and continuous efforts by players towards developing child-friendly drugs, the pediatric clinical trials market is poised to experience strong growth over the forthcoming years.

Market Dynamics:

The global pediatric clinical trials market growth is driven by the rising incidence of chronic diseases among children, growing demand for new treatment modalities, and initiatives undertaken by regulatory bodies to streamline drug development process. In 2021, as per WHO estimates, over 200 million children suffer from various non-communicable illnesses worldwide. High unmet clinical needs have encouraged pharmaceutical companies to boost investments towards developing specialized treatments for pediatric population. Favorable regulations such as the U.S. Food and Drug Administration's amendments Act 2012 have mandated pre-marketing clinical evaluation of drugs for pediatric use, thereby augmenting market opportunities. However, complexities involved in pediatric clinical research and lack of sufficient surrogate endpoints continue to negatively impact market growth. High costs associated with trials and inadequate number of experienced clinical investigators also impede broader market adoption. Nevertheless, continual collaborations between industry players and research organizations to address issues through novel approaches will support future expansion.

Key Features of the Study:

• This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pediatric clinical trials market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market

Market Segmentation

• Phase Insights (Revenue, USD Bn, 2019-2031)
• Phase I
• Phase II
• Phase III
• Phase IV
• Study Design Insights (Revenue, USD Bn, 2019-2031)
• Treatment Studies
• Observational Studies
• Therapeutic Area Insights (Revenue, USD Bn, 2019-2031)
• Respiratory Diseases
• Cardiovascular Diseases
• Neuropsychiatric Conditions
• Oncology
• Diabetes
• Others (Neuropsychiatric Conditions, etc.)
• Regional Insights (Revenue, USD Bn, 2019-2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• CSL Behring
• Sanofi
• Takeda Pharmaceutical Company Limited
• Orchard Therapeutics plc.
• Pharming Group N.V.
• BioCryst Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Attune Pharmaceuticals
• Arrowhead Pharmaceuticals, Inc.
• Adverum Biotechnologies, Inc.
• KalVista Pharmaceuticals
• CENTOGENE N.V.